P/E of 15.4 suggests value, but gross margins at historic 31.1% warn that some bargains aren't worth catching.
With -0.16% growth implied by the market versus 7% historical, expectations are finally reasonable—but the business keeps deteriorating.
What does this company do and how does it make money?
CTSH operates a traditional IT services model spread across four industry verticals, with Healthcare and Financial Services dominating the revenue mix. The heavy North American exposure (74.8%) creates both stability and concentration risk, while the 7% growth rate places it squarely in the mature technology services category.
Five legendary investment frameworks analyzed this company.
Buffett sees a cigar butt at 15.4x earnings while Marks spots asymmetry in 0th percentile margins—but with gross margins collapsing from 40% to 31% over nine years, is CTSH's $2.6B cash flow a lifeline or a countdown? Tap any framework below to explore their full analysis.
How much cash does it generate and where does it go?
CTSH generates substantial cash ($2.6B FCF) and returns most of it to shareholders, but the buyback timing has been catastrophic—destroying $2.3B in value by purchasing shares 41.5% above current prices. The minimal capex spend (1.4% of revenue) reflects the asset-light model but also raises questions about growth investment.
Is the business getting stronger or weaker?
The business faces a fundamental contradiction: revenue hits record levels while gross margins plunge to historic lows, suggesting growth is coming at the expense of unit economics. The ROIC below cost of capital (3.64% vs 8.44% WACC) confirms value destruction despite operational cash generation.
What could go wrong and has it survived trouble before?
The company shows operational resilience (B grade) with quick recoveries from shocks, but the 75.5% FCF decline during the 2022 rate spike reveals severe interest rate sensitivity. The recent insider buying shift suggests management sees value, though their corporate buyback program has destroyed billions.
At 31.1% gross margins—the lowest in company history—CTSH generates $2.6B in free cash flow while destroying value with ROIC of 3.64% versus 8.44% WACC.
Is the stock priced for perfection, fair value, or pessimism?
The market has given up on CTSH, pricing in negative growth despite consistent execution (79% double beat rate) and implying the business will shrink. Trading at a 271bp discount to treasuries and 40% below DCF value, the stock reflects deep pessimism about margin recovery.
Analysis applies published investment frameworks to publicly available financial data. Educational purposes only. Not financial advice.